We identified a novel variant, AR-v19, which localizes to the nucleus, is expressed in multiple BlCa cell lines and tumors and transactivates transcription from an AR-regulated promoter in a dose dependent manner14. The gene discussed is AR; the disease is bladder transitional cell carcinoma.